Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Active Immunotherapy With Ad5 [E1-,E2b-]-CEA(6D) Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA

NCT01147965 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT01147965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Active Immunotherapy With Ad5 [E1-,E2b-]-CEA(6D) Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Lead sponsor
NantCell, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 16, 2010
Completion date
May 31, 2017
Enrollment
43 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, lung cancer, prostate cancer